Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03090191




Registration number
NCT03090191
Ethics application status
Date submitted
20/03/2017
Date registered
24/03/2017
Date last updated
13/02/2023

Titles & IDs
Public title
Clostridium Difficile Vaccine Efficacy Trial
Scientific title
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Secondary ID [1] 0 0
2016-003866-14
Secondary ID [2] 0 0
B5091007
Universal Trial Number (UTN)
Trial acronym
Clover
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Clostridium Difficile Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Clostridium difficile vaccine
Treatment: Other - Placebo

Experimental: Clostridium difficile vaccine -

Placebo comparator: Placebo -


Treatment: Other: Clostridium difficile vaccine
Toxoid-based Clostridium difficile vaccine

Treatment: Other: Placebo
Normal saline solution (0.9% sodium chloride)
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3
Timepoint [1] 0 0
From 14 days after Dose 3 to the end of the surveillance period (mean follow-up after dose 3 was 34.2 months)
Primary outcome [2] 0 0
Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 2
Timepoint [2] 0 0
From 14 days after Dose 2 to the end of the surveillance period (mean follow-up after dose 2 was 36 months)
Primary outcome [3] 0 0
Percentage of Participants Reporting Local Reactions Within 7 Days After Dose 1
Timepoint [3] 0 0
Within 7 days after Dose 1 at Month 0
Primary outcome [4] 0 0
Percentage of Participants Reporting Local Reactions Within 7 Days After Dose 2
Timepoint [4] 0 0
Within 7 days after Dose 2 at Month 1
Primary outcome [5] 0 0
Percentage of Participants Reporting Local Reactions Within 7 Days After Dose 3
Timepoint [5] 0 0
Within 7 days after Dose 3 at Month 6
Primary outcome [6] 0 0
Percentage of Participants Reporting Systemic Events Within 7 Days After Dose 1
Timepoint [6] 0 0
Within 7 days after Dose 1 at Month 0
Primary outcome [7] 0 0
Percentage of Participants Reporting Systemic Events Within 7 Days After Dose 2
Timepoint [7] 0 0
Within 7 days after Dose 2 at Month 1
Primary outcome [8] 0 0
Percentage of Participants Reporting Systemic Events Within 7 Days After Dose 3
Timepoint [8] 0 0
Within 7 days after Dose 3 at Month 6
Primary outcome [9] 0 0
Number of Participants Reporting Adverse Events (AEs)
Timepoint [9] 0 0
From Day 1 of Dose 1 to 1 Month after Dose 3 (7 Months)
Primary outcome [10] 0 0
Number of Participants Reporting Serious Adverse Events (SAEs)
Timepoint [10] 0 0
From Day 1 of Dose 1 up to 6 months after Dose 3 (up to Month 12)
Secondary outcome [1] 0 0
Number of All Episodes of CDI (Definition 1 and 2) After Dose 3
Timepoint [1] 0 0
From 14 days after Dose 3 to the end of the surveillance period (mean follow-up after dose 3 was 34.2 months)
Secondary outcome [2] 0 0
Time to Resolution for Participants With First Primary Episodes of CDI (Definition 1) After Dose 3
Timepoint [2] 0 0
From 14 days after Dose 3 to the end of the surveillance period (mean follow-up after dose 3 was 34.2 months)
Secondary outcome [3] 0 0
Proportion of Participants Who Required Medical Attention During First Primary Episode of CDI (Definition 1) After Dose 3
Timepoint [3] 0 0
From 14 days after Dose 3 to the end of the surveillance period (mean follow-up after dose 3 was 34.2 months)
Secondary outcome [4] 0 0
Number of Participants With Recurrent Episodes of CDI (Definition 2) After Dose 3
Timepoint [4] 0 0
From 14 days after Dose 3 to the end of the surveillance period (mean follow-up after dose 3 was 34.2 months)
Secondary outcome [5] 0 0
Number of All Episodes of CDI (Definition 1 and 2) After Dose 2
Timepoint [5] 0 0
From 14 days after Dose 2 to the end of the surveillance period (mean follow-up after dose 2 was 36 months)
Secondary outcome [6] 0 0
Number of Participants With Recurrent Episodes of CDI (Definition 2) After Dose 2
Timepoint [6] 0 0
From 14 days after Dose 2 to the end of the surveillance period (mean follow-up after dose 2 was 36 months)
Secondary outcome [7] 0 0
Number of First Primary Episode of CDI (Definition 1) After Dose 2 and Before Dose 3
Timepoint [7] 0 0
From 14 days after Dose 2 to Dose 3 or the day the third vaccination was expected (168 days after Dose 2) for participants who received only 2 doses
Secondary outcome [8] 0 0
Number of Participants With Recurrent Episode of CDI (Definition 2) After Dose 2 and Before Dose 3
Timepoint [8] 0 0
From 14 days after Dose 2 to Dose 3 or the day the third vaccination was expected (168 days after Dose 2) for participants who received only 2 doses

Eligibility
Key inclusion criteria
* Evidence of a personally signed and dated informed consent document.
* Willing and able to comply with study procedures.
* Subjects with an increased risk of future contact with healthcare systems or subjects who have received systemic antibiotics in the previous 12 weeks.
* Ability to be contacted by telephone during study participation.
* Negative urine pregnancy test for female subjects of childbearing potential.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
* Participation in other studies involving investigational drug(s)/vaccine(s) within 28 days prior to study entry until 1 month after the third vaccination.
* Previous administration of an investigational C difficile vaccine or C difficile mAb therapy.
* Prior episode of CDI..
* Receipt of blood products or immunoglobulins within 6 months before enrollment.
* Subjects who may be unable to respond to vaccination due to:

* Metastatic malignancy; or
* End-stage renal disease; or
* Any serious medical disorder likely to be fatal within the next 12 months; or
* Congenital or acquired immunodeficiency; or
* Receipt of high dose systemic corticosteroids for 14 days within 28 days of enrollment; or
* Receipt of chronic systemic treatment with other known immunosuppressant medications, or radiotherapy, within 6 months of enrollment.
* Known infection with human immunodeficiency virus (HIV).
* Any bleeding disorder or anticoagulant therapy that would contraindicate intramuscular injection.
* Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.
* Prior small- or large-bowel resection.
* Any condition or treatment resulting in frequent diarrhea.
* Other acute or chronic condition or abnormality that may increase the risk associated with study participation or IP administration or may interfere with interpretation of study results
* Pregnant or breastfeeding female subjects; male subjects and female subjects who are sexually active and at risk for pregnancy and will not/cannot use 2 methods of contraception

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/03/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/12/2021
Sample size
Target
Accrual to date
Final
17535
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Paratus Clinical Pty Ltd - Kanwal
Recruitment hospital [2] 0 0
Australian Clinical Research Network - Maroiubra
Recruitment hospital [3] 0 0
Maroubra Medical Centre - Maroubra
Recruitment hospital [4] 0 0
University Clinic Pharmacy - Westmead
Recruitment hospital [5] 0 0
Westmead Hospital - Westmead
Recruitment hospital [6] 0 0
Austrials Pty Ltd - Sherwood
Recruitment hospital [7] 0 0
Mater Misericordiae Ltd & Mater Medical Research Institute Ltd - South Brisbane
Recruitment hospital [8] 0 0
Eastern Health - Box Hill Hospital - Box Hill
Recruitment hospital [9] 0 0
Emeritus Research - Camberwell
Recruitment hospital [10] 0 0
Barwon Health - Geelong
Recruitment hospital [11] 0 0
Linear Clinical Research - Nedlands
Recruitment hospital [12] 0 0
Australian Clinical Research Network - Maroubra
Recruitment postcode(s) [1] 0 0
2259 - Kanwal
Recruitment postcode(s) [2] 0 0
2035 - Maroiubra
Recruitment postcode(s) [3] 0 0
2035 - Maroubra
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment postcode(s) [5] 0 0
4075 - Sherwood
Recruitment postcode(s) [6] 0 0
4101 - South Brisbane
Recruitment postcode(s) [7] 0 0
3128 - Box Hill
Recruitment postcode(s) [8] 0 0
3124 - Camberwell
Recruitment postcode(s) [9] 0 0
3220 - Geelong
Recruitment postcode(s) [10] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Hawaii
Country [10] 0 0
United States of America
State/province [10] 0 0
Idaho
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Indiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Iowa
Country [14] 0 0
United States of America
State/province [14] 0 0
Kansas
Country [15] 0 0
United States of America
State/province [15] 0 0
Kentucky
Country [16] 0 0
United States of America
State/province [16] 0 0
Louisiana
Country [17] 0 0
United States of America
State/province [17] 0 0
Maryland
Country [18] 0 0
United States of America
State/province [18] 0 0
Michigan
Country [19] 0 0
United States of America
State/province [19] 0 0
Minnesota
Country [20] 0 0
United States of America
State/province [20] 0 0
Mississippi
Country [21] 0 0
United States of America
State/province [21] 0 0
Missouri
Country [22] 0 0
United States of America
State/province [22] 0 0
Montana
Country [23] 0 0
United States of America
State/province [23] 0 0
Nebraska
Country [24] 0 0
United States of America
State/province [24] 0 0
New Jersey
Country [25] 0 0
United States of America
State/province [25] 0 0
New Mexico
Country [26] 0 0
United States of America
State/province [26] 0 0
New York
Country [27] 0 0
United States of America
State/province [27] 0 0
North Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
North Dakota
Country [29] 0 0
United States of America
State/province [29] 0 0
Ohio
Country [30] 0 0
United States of America
State/province [30] 0 0
Oklahoma
Country [31] 0 0
United States of America
State/province [31] 0 0
Oregon
Country [32] 0 0
United States of America
State/province [32] 0 0
Pennsylvania
Country [33] 0 0
United States of America
State/province [33] 0 0
Rhode Island
Country [34] 0 0
United States of America
State/province [34] 0 0
South Carolina
Country [35] 0 0
United States of America
State/province [35] 0 0
Tennessee
Country [36] 0 0
United States of America
State/province [36] 0 0
Texas
Country [37] 0 0
United States of America
State/province [37] 0 0
Utah
Country [38] 0 0
United States of America
State/province [38] 0 0
Virginia
Country [39] 0 0
United States of America
State/province [39] 0 0
Washington
Country [40] 0 0
United States of America
State/province [40] 0 0
Wisconsin
Country [41] 0 0
Argentina
State/province [41] 0 0
Buenos Aires
Country [42] 0 0
Argentina
State/province [42] 0 0
Santa FE
Country [43] 0 0
Argentina
State/province [43] 0 0
Cordoba
Country [44] 0 0
Belgium
State/province [44] 0 0
Brussels
Country [45] 0 0
Belgium
State/province [45] 0 0
Leuven
Country [46] 0 0
Belgium
State/province [46] 0 0
Liege
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Kazanlak
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Kozloduy
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Lom
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Pleven
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Plovdiv
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Ruse
Country [53] 0 0
Bulgaria
State/province [53] 0 0
Sevlievo
Country [54] 0 0
Bulgaria
State/province [54] 0 0
Silistra
Country [55] 0 0
Bulgaria
State/province [55] 0 0
Sliven
Country [56] 0 0
Bulgaria
State/province [56] 0 0
Sofia
Country [57] 0 0
Bulgaria
State/province [57] 0 0
Troyan
Country [58] 0 0
Bulgaria
State/province [58] 0 0
Veliko Tarnovo
Country [59] 0 0
Bulgaria
State/province [59] 0 0
Vidin
Country [60] 0 0
Canada
State/province [60] 0 0
British Columbia
Country [61] 0 0
Canada
State/province [61] 0 0
Ontario
Country [62] 0 0
Canada
State/province [62] 0 0
Quebec
Country [63] 0 0
Chile
State/province [63] 0 0
IX Region DE LA Araucania
Country [64] 0 0
Chile
State/province [64] 0 0
Region DE Antofagasta
Country [65] 0 0
Chile
State/province [65] 0 0
Region DE LA Araucania
Country [66] 0 0
Chile
State/province [66] 0 0
Región Metropolitana
Country [67] 0 0
Colombia
State/province [67] 0 0
Antioquia
Country [68] 0 0
Colombia
State/province [68] 0 0
Atlantico
Country [69] 0 0
Colombia
State/province [69] 0 0
Caldas
Country [70] 0 0
Colombia
State/province [70] 0 0
D.c.
Country [71] 0 0
Colombia
State/province [71] 0 0
Quindío
Country [72] 0 0
Colombia
State/province [72] 0 0
Santander
Country [73] 0 0
Colombia
State/province [73] 0 0
Valle DEL Cauca
Country [74] 0 0
Czechia
State/province [74] 0 0
Czech
Country [75] 0 0
Czechia
State/province [75] 0 0
Benatky nad Jizerou
Country [76] 0 0
Czechia
State/province [76] 0 0
Kyjov
Country [77] 0 0
Czechia
State/province [77] 0 0
Opava
Country [78] 0 0
Czechia
State/province [78] 0 0
Policka
Country [79] 0 0
Czechia
State/province [79] 0 0
Praha 5
Country [80] 0 0
Czechia
State/province [80] 0 0
Pribram I.
Country [81] 0 0
Czechia
State/province [81] 0 0
Roznov pod Radhostem
Country [82] 0 0
Czechia
State/province [82] 0 0
Slany
Country [83] 0 0
Czechia
State/province [83] 0 0
Usti nad Labem
Country [84] 0 0
Finland
State/province [84] 0 0
Helsinki
Country [85] 0 0
Finland
State/province [85] 0 0
Kokkola
Country [86] 0 0
Finland
State/province [86] 0 0
Oulu
Country [87] 0 0
Finland
State/province [87] 0 0
Pori
Country [88] 0 0
Finland
State/province [88] 0 0
Tampere
Country [89] 0 0
Finland
State/province [89] 0 0
Turku
Country [90] 0 0
France
State/province [90] 0 0
Dijon cedex
Country [91] 0 0
France
State/province [91] 0 0
Paris
Country [92] 0 0
France
State/province [92] 0 0
Saint Priest en Jarez
Country [93] 0 0
France
State/province [93] 0 0
Tours Cedex 09
Country [94] 0 0
Germany
State/province [94] 0 0
Berlin
Country [95] 0 0
Germany
State/province [95] 0 0
Cottbus
Country [96] 0 0
Germany
State/province [96] 0 0
Dresden
Country [97] 0 0
Germany
State/province [97] 0 0
Essen
Country [98] 0 0
Germany
State/province [98] 0 0
Leipzig
Country [99] 0 0
Germany
State/province [99] 0 0
Rostock
Country [100] 0 0
Germany
State/province [100] 0 0
Westerstede
Country [101] 0 0
Germany
State/province [101] 0 0
Wuerzburg
Country [102] 0 0
Hungary
State/province [102] 0 0
Baja
Country [103] 0 0
Hungary
State/province [103] 0 0
Balatonfured
Country [104] 0 0
Hungary
State/province [104] 0 0
Budapest
Country [105] 0 0
Hungary
State/province [105] 0 0
Debrecen
Country [106] 0 0
Hungary
State/province [106] 0 0
Encs
Country [107] 0 0
Hungary
State/province [107] 0 0
Kaposvar
Country [108] 0 0
Japan
State/province [108] 0 0
Aichi
Country [109] 0 0
Japan
State/province [109] 0 0
Fukuoka
Country [110] 0 0
Japan
State/province [110] 0 0
Hiroshima
Country [111] 0 0
Japan
State/province [111] 0 0
Hokkaido
Country [112] 0 0
Japan
State/province [112] 0 0
Ibaraki
Country [113] 0 0
Japan
State/province [113] 0 0
Kanagawa
Country [114] 0 0
Japan
State/province [114] 0 0
Miyagi
Country [115] 0 0
Japan
State/province [115] 0 0
Nagano Prefecture
Country [116] 0 0
Japan
State/province [116] 0 0
Osaka
Country [117] 0 0
Japan
State/province [117] 0 0
Shiga
Country [118] 0 0
Japan
State/province [118] 0 0
Shizuoka
Country [119] 0 0
Japan
State/province [119] 0 0
Tokyo
Country [120] 0 0
Japan
State/province [120] 0 0
Fukui
Country [121] 0 0
Japan
State/province [121] 0 0
Kumamoto
Country [122] 0 0
Japan
State/province [122] 0 0
Saga
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Gangwon-do
Country [124] 0 0
Korea, Republic of
State/province [124] 0 0
Gyeonggi-do
Country [125] 0 0
Korea, Republic of
State/province [125] 0 0
Seoul
Country [126] 0 0
Korea, Republic of
State/province [126] 0 0
Busan
Country [127] 0 0
Korea, Republic of
State/province [127] 0 0
Daegu
Country [128] 0 0
Korea, Republic of
State/province [128] 0 0
Incheon
Country [129] 0 0
Peru
State/province [129] 0 0
Lima
Country [130] 0 0
Peru
State/province [130] 0 0
Cusco
Country [131] 0 0
Peru
State/province [131] 0 0
Trujillo, La Libertad
Country [132] 0 0
Poland
State/province [132] 0 0
Bydgoszcz
Country [133] 0 0
Poland
State/province [133] 0 0
Gdansk
Country [134] 0 0
Poland
State/province [134] 0 0
Gdynia
Country [135] 0 0
Poland
State/province [135] 0 0
Katowice
Country [136] 0 0
Poland
State/province [136] 0 0
Leczna
Country [137] 0 0
Poland
State/province [137] 0 0
Poznan
Country [138] 0 0
Poland
State/province [138] 0 0
Warszawa
Country [139] 0 0
Poland
State/province [139] 0 0
Wroclaw
Country [140] 0 0
Portugal
State/province [140] 0 0
Almada
Country [141] 0 0
Portugal
State/province [141] 0 0
Aveiro
Country [142] 0 0
Portugal
State/province [142] 0 0
Braga
Country [143] 0 0
Portugal
State/province [143] 0 0
Guimaraes
Country [144] 0 0
Portugal
State/province [144] 0 0
Vila Nova de Gaia
Country [145] 0 0
Slovakia
State/province [145] 0 0
Bojnice
Country [146] 0 0
Slovakia
State/province [146] 0 0
Bratislava
Country [147] 0 0
Slovakia
State/province [147] 0 0
Kosice
Country [148] 0 0
Slovakia
State/province [148] 0 0
Nitra
Country [149] 0 0
Slovakia
State/province [149] 0 0
Nove Zamky
Country [150] 0 0
Slovakia
State/province [150] 0 0
Piestany
Country [151] 0 0
Slovakia
State/province [151] 0 0
Pruske
Country [152] 0 0
Slovakia
State/province [152] 0 0
Rimavska Sobota
Country [153] 0 0
Slovakia
State/province [153] 0 0
Spisska Nova Ves
Country [154] 0 0
Slovakia
State/province [154] 0 0
Stara Tura
Country [155] 0 0
Slovakia
State/province [155] 0 0
Trencin
Country [156] 0 0
Slovakia
State/province [156] 0 0
Trnava
Country [157] 0 0
Spain
State/province [157] 0 0
Barcelona
Country [158] 0 0
Spain
State/province [158] 0 0
A Coruna
Country [159] 0 0
Spain
State/province [159] 0 0
Madrid
Country [160] 0 0
Spain
State/province [160] 0 0
Sevilla
Country [161] 0 0
Spain
State/province [161] 0 0
Valencia
Country [162] 0 0
Sweden
State/province [162] 0 0
Eskilstuna
Country [163] 0 0
Sweden
State/province [163] 0 0
Goteborg
Country [164] 0 0
Sweden
State/province [164] 0 0
Göteborg
Country [165] 0 0
Sweden
State/province [165] 0 0
Orebro
Country [166] 0 0
Sweden
State/province [166] 0 0
Stockholm
Country [167] 0 0
Taiwan
State/province [167] 0 0
Taiwan (r.o.c.)
Country [168] 0 0
Taiwan
State/province [168] 0 0
New Taipei City
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taipei
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Cheshire
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Cornwall
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Devon
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Lancashire
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Leicestershire
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Midlothian
Country [176] 0 0
United Kingdom
State/province [176] 0 0
WEST Midlands
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Leeds
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Newcastle upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated.

Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.
Trial website
https://clinicaltrials.gov/study/NCT03090191
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03090191